Cubist Pharmaceuticals to Announce First Quarter 2008 Financial Results on Thursday,...

Cubist Pharmaceuticals to Announce First Quarter 2008 Financial Results on Thursday, April 17, 2008

Conference Call to be Held at 5:00 p.m. EDT
LEXINGTON, Mass.--(Business Wire)--
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its first
quarter 2008 financial results at 4:00 p.m. EDT on Thursday, April
17th, 2008. In connection with this announcement, Cubist will host a
conference call and live audio webcast (with slides) at 5:00 p.m. EDT
that same day to discuss its first quarter financial results, business
activities and financial outlook.

As always, the quarterly earnings call will be available via phone
and webcast. The phone call dial-in information is listed below. To
access the webcast, please log on to the Cubist website at
www.cubist.com at least 15 minutes prior to the start of the call to
ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available on
Cubist's website beginning approximately three hours after the call.

**************CONFERENCE CALL & WEBCAST INFORMATION**************

Cubist will host a conference call and live audio webcast to
discuss its first quarter 2008

financial results, business activities and financial outlook.

WHEN: Thursday, April 17, 2008 at 5:00 p.m. EDT

LIVE DOMESTIC & CANADA CALL-IN: 877-407-0778

LIVE INTERNATIONAL CALL-IN: 201-689-8565

24-HOUR REPLAY DOMESTIC & CANADA: 877-660-6853

24-HOUR REPLAY INTERNATIONAL: 201-612-7415

REPLAY PASSCODES (BOTH REQUIRED FOR PLAYBACK):

ACCOUNT #: 286 CONFERENCE ID #: 274880

CALL WILL ALSO BE BROADCAST LIVE, LISTEN ONLY, VIA THE WEB AT:
www.cubist.com

Replay will be available for 30 days at www.cubist.com

********************************************************************

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the research, development, and commercialization of
pharmaceutical products that address unmet medical needs in the acute
care environment. In the U.S., Cubist markets CUBICIN(R) (daptomycin
for injection), the first antibiotic in a new class of anti-infectives
called lipopeptides. The Cubist product pipeline includes pre-clinical
programs that address unmet medical need in Gram-positive infections,
Gram-negative infections, CDAD (Clostridium difficile-associated
diarrhea), and HCV (Hepatitis C infections.) Cubist is headquartered
in Lexington, MA. Additional information can be found at Cubist's web
site at www.cubist.com.

Cubist and CUBICIN are registered trademarks of Cubist
Pharmaceuticals, Inc.

Cubist Pharmaceuticals, Inc.
Eileen C. McIntyre, 781-860-8533
Senior Director, Corporate Communications
eileen.mcintyre@cubist.com

Copyright Business Wire 2008